派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02565 派格生物医药-B

已收盘 07-27 16:08:04

6.340

-0.050

-0.78%

最高6.600	最低6.230	成交量592.68万
今开6.390	昨收6.390	日振幅5.79%
总市值24.79亿	流通市值24.47亿	总股本3.91亿
成交额3,791万	换手率1.54%	流通股本3.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02565","market":"HK","secType":"STK","nameCN":"派格生物医药-B","latestPrice":6.34,"timestamp":1785139684002,"preClose":6.39,"halted":0,"volume":5926750,"delay":0,"changeRate":-0.007824726134585262,"floatShares":386000000,"shares":391000000,"eps":-0.6375448942143317,"marketStatus":"已收盘","change":-0.05,"latestTime":"07-27 16:08:04","open":6.39,"high":6.6,"low":6.23,"amount":37911721,"amplitude":0.057903,"askPrice":6.35,"askSize":7000,"bidPrice":6.34,"bidSize":29000,"shortable":3,"etf":0,"ttmEps":-0.6383145847775287,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785202200000},"marketStatusCode":5,"adr":0,"listingDate":1748275200000,"exchange":"SEHK","adjPreClose":6.39,"openAndCloseTimeList":[[1785115800000,1785124800000],[1785128400000,1785139200000]],"volumeRatio":0.303062,"lotSize":50,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02565","defaultTab":"news","newsList":[{"id":"1177397709","title":"异动解读｜派格生物医药-B盘中下跌8.12%，报6.34港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177397709","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177397709?lang=zh_cn&edition=full","pubTime":"2026-07-24 14:00","pubTimestamp":1784872801,"startTime":"0","endTime":"0","summary":"7月24日，派格生物医药-B盘中下跌8.12%，报6.34港元/股，成交额4470.26万港元。派格生物医药-B所在的生物科技行业中，个股中，信达生物跌1.48%，百济神州涨2.48%，康方生物跌3.89%，科伦博泰生物跌1.34%，三生制药跌2.16%。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653775152","title":"首批处方落地即触发4900万港元权益金 派格生物(02565.HK)商业化进入价值兑现期","url":"https://stock-news.laohu8.com/highlight/detail?id=2653775152","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653775152?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:30","pubTimestamp":1784716234,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02565","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152538651","title":"派格生物医药-B(02565)派达康®落地全国首批商业化处方 触发4,900万港元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1152538651","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152538651?lang=zh_cn&edition=full","pubTime":"2026-07-22 18:05","pubTimestamp":1784714748,"startTime":"0","endTime":"0","summary":"2026年7月22日，派格生物医药-B发布自愿性公告称，其自主研发的长效GLP-1受体激动剂维培那肽注射液已在北京大学人民医院、中南大学湘雅二医院等多家医疗机构开出全国首批商业化处方。腾瑞制药已书面确认，将支付约港币4,900万元的第二笔权益金，派格生物医药-B预计在协议约定期限内收取该款项。加上即将到账的4,900万元，派达康在商业化合作层面的里程碑付款持续推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132079551","title":"异动解读｜派格生物医药-B盘中上涨8.04%，三方战略合作加速派达康商业化放量预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1132079551","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132079551?lang=zh_cn&edition=full","pubTime":"2026-07-21 14:58","pubTimestamp":1784617128,"startTime":"0","endTime":"0","summary":"7月21日，派格生物医药-B盘中上涨8.04%，报7.39港元，成交额1.47亿港元。消息面上，7月17日，派格生物医药-B与上海腾瑞制药及阿里健康在杭州正式签署战略合作协议，三方将整合医药研发、生产及数字化健康服务资源，共同推进核心产品派达康的商业化进程。派达康已获批用于成人2型糖尿病治疗，属独家品种，并已通过国家医保目录调整初步形式审查。市场关注重点已由产品获批转向医院覆盖及线上线下协同带来的放量速度。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652235261","title":"港股异动 | 派格生物医药-B(02565)涨超5% 携手三方共同加速打通派达康商业化链路 产品市场放量蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652235261","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652235261?lang=zh_cn&edition=full","pubTime":"2026-07-20 11:43","pubTimestamp":1784519009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B涨超5%，截至发稿，涨5.41%，报7.01港元，报1.32亿港元。消息面上，7月17日，派格生物医药-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。下一阶段，市场对派达康的关注重点，将由“产品能否获批”转向医院覆盖、医生处方、患者持续用药以及线上线下协同带来的放量速度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","BK4581","BK1161","BK4585","VXUS","02565","BK4588","399441","161726","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196884965","title":"阿里健康宣布与天力士制药、派格生物医药就GLP-1RA药物达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1196884965","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1196884965?lang=zh_cn&edition=full","pubTime":"2026-07-17 19:58","pubTimestamp":1784289496,"startTime":"0","endTime":"0","summary":"阿里健康发布公告称，已与天力士制药及派格生物医药-B正式签署关于GLP-1RA药物的战略合作协议。此举旨在整合各方在医药研发、生产及数字化健康服务领域的优势资源，共同推进该创新药物的开发与商业化进程。GLP-1RA类药物近年来在全球糖尿病及肥胖症治疗市场备受关注，市场潜力巨大。通过此次合作，阿里健康有望进一步强化其医药健康生态布局，而天力士制药与派格生物医药-B则将借助阿里健康的平台与用户基础，加速产品市场渗透。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1189","BK1617","BK1142","BK1515","BK1610","BK1247","BK1501","BK1502","BK1591","HK0000165453.HKD","BK1571","02565","00241","BK1615","BK1584","BK1589","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652404980","title":"派格生物-B(02565)联手腾瑞制药、阿里健康，派达康商业化链路加速打通，市场放量蓄势待发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652404980","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652404980?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月17日，派格生物-B、上海腾瑞制药股份有限公司与阿里健康在杭州正式签署战略合作协议。派达康已获批用于成人2型糖尿病治疗。对于派格生物而言，此次与腾瑞制药、阿里健康达成战略合作，不仅进一步完善了派达康的商业化版图，也释放出更加清晰的信号：随着产品差异化、全国推广网络和数字化患者入口逐步汇合，派达康正由商业化准备阶段加速驶入真实市场验证阶段，后续放量已蓄势待发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469039.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1584","BK1615","BK1502","BK1247","BK1610","BK1161","HK0000165453.HKD","BK1574","BK1591","BK1501","02565","BK1191","BK1589","BK1515","00241","BK1189","BK1571","BK1142","01477","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142608450","title":"异动解读｜派格生物医药-B盘中下跌8.04%，Rani合作催化消退叠加生物科技板块集体走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1142608450","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142608450?lang=zh_cn&edition=full","pubTime":"2026-07-17 10:16","pubTimestamp":1784254603,"startTime":"0","endTime":"0","summary":"7月17日，派格生物医药-B盘中下跌8.04%，报6.2港元，成交额4767.38万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%后持续波动，本次下跌系前期催化效应消退后获利盘持续兑现。同日生物科技板块整体承压，康方生物跌9.68%，三生制药跌9.21%，科伦博泰生物跌4.38%，信达生物跌3.77%，百济神州跌2.73%，板块联动效应加剧个股抛压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142511876","title":"异动解读｜派格生物医药-B盘中上涨8.78%，Rani合作催化叠加前日回调后技术性反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=1142511876","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142511876?lang=zh_cn&edition=full","pubTime":"2026-07-15 09:46","pubTimestamp":1784079975,"startTime":"0","endTime":"0","summary":"7月15日，派格生物医药-B盘中上涨8.78%，报6.82港元，成交额7200.29万港元。公司此前因与纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日大涨约29%，7月13日续涨逾4%后，7月14日因获利盘集中兑现回调约8%，本次上涨系短期超跌后的技术性修复。该谅解备忘录有效期三年，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物多项肥胖症及代谢疾病候选资产开展口服制剂筛选及临床前开发，并探索中国以外市场的商业化合作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155910722","title":"异动解读｜派格生物医药-B盘中下跌8.11%，牵手Rani大涨后短期获利回吐压力显现","url":"https://stock-news.laohu8.com/highlight/detail?id=1155910722","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155910722?lang=zh_cn&edition=full","pubTime":"2026-07-14 13:28","pubTimestamp":1784006905,"startTime":"0","endTime":"0","summary":"7月14日，派格生物医药-B盘中下跌8.11%，报5.89港元，成交额1.2亿港元。公司此前因与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，股价于7月10日单日大涨约29%，7月13日继续上涨逾4%，短期累计涨幅显著，本次回调与前期快速拉升后获利盘集中兑现有关。该谅解备忘录有效期三年，目前仍处于早期筛选阶段，距离实质性临床推进及商业化落地仍有较长路径，市场对短期兑现预期有所降温。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103356834","title":"异动解读｜派格生物医药-B盘中上涨8.42%，牵手Rani推进代谢资产口服化持续获市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1103356834","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103356834?lang=zh_cn&edition=full","pubTime":"2026-07-13 09:45","pubTimestamp":1783907137,"startTime":"0","endTime":"0","summary":"7月13日，派格生物医药-B盘中上涨8.42%，报7.47港元，成交额1.05亿港元，延续上周五大涨势头。消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。该合作为公司下一代代谢管线叠加口服新剂型及海外开发路径，市场情绪持续发酵。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112166568","title":"异动解读｜派格生物医药-B盘中上涨38.16%，牵手Rani推进代谢创新资产口服化开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1112166568","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112166568?lang=zh_cn&edition=full","pubTime":"2026-07-10 11:08","pubTimestamp":1783652923,"startTime":"0","endTime":"0","summary":"7月10日，派格生物医药-B盘中上涨38.16%，报7.64港元，成交额5.3亿港元。消息面上，公司于7月8日与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录，双方将依托Rani专有的RaniPill口服生物药递送平台，围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产，开展口服制剂筛选及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。双方计划从派格生物多项代谢创新资产中筛选适合口服递送的候选项目，推动最具潜力项目进入临床开发。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650905037","title":"派格生物医药-B与Rani签署谅解备忘录推进口服制剂开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2650905037","media":"财中社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650905037?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:09","pubTimestamp":1783649340,"startTime":"0","endTime":"0","summary":"7月10日，派格生物医药-B（02565）发布公告，公司于2026年7月8日与美国纳斯达克上市公司RaniTherapeuticsHoldings,Inc.签署了谅解备忘录，旨在推进多项代谢创新资产的口服化开发。根据谅解备忘录，双方将依托Rani的RaniPill?口服生物药递送平台，围绕公司的多项肥胖症及代谢疾病候选资产，开展口服制剂的筛选及临床前开发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607103801259725.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801259725.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","399441","BK4581","XBI","BK4585","02565","BK4588","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136222445","title":"派格生物医药-B盘初一度飙涨逾20%，牵手Rani推进多项代谢创新资产口服化","url":"https://stock-news.laohu8.com/highlight/detail?id=1136222445","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136222445?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:47","pubTimestamp":1783648028,"startTime":"0","endTime":"0","summary":"7月10日，$派格生物医药-B$盘初一度飙涨逾20%，牵手Rani推进多项代谢创新资产口服化。双方拟围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产，利用Rani专有的RaniPill平台开展口服递送及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。根据Rani披露的信息，双方计划从派格生物的多项代谢创新资产中筛选适合口服递送的候选项目，并以推动其中最具潜力的项目进入临床开发为目标。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4581","XBI","BK4585","02565","BK4588","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650903069","title":"港股异动 | 派格生物医药-B(02565)大涨超21% 牵手Rani推进多项代谢创新资产口服化","url":"https://stock-news.laohu8.com/highlight/detail?id=2650903069","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650903069?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:36","pubTimestamp":1783647407,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，派格生物医药-B大涨超21%，截至发稿，涨21.88%，报6.77港元，成交额6080.69万港元。双方拟围绕派格生物肥胖症及代谢疾病管线中的多项创新候选资产，利用Rani专有的RaniPill平台开展口服递送及临床前开发，并探索相关产品在中国以外市场的研发、生产及商业化合作。根据Rani披露的信息，双方计划从派格生物的多项代谢创新资产中筛选适合口服递送的候选项目，并以推动其中最具潜力的项目进入临床开发为目标。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["399441","XBI","BK1161","BK4585","KCAI","VXUS","BK4581","BK4588","02565","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650058019","title":"港股开盘向好 恒指高开0.76% 联想集团(00992)涨8.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650058019","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650058019?lang=zh_cn&edition=full","pubTime":"2026-07-10 09:30","pubTimestamp":1783647034,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股开盘向好，恒指高开0.76%，国企指数高开0.85%，恒生科技指数高开1.25%。瑞浦兰钧高开5.4%，公司发盈喜，预期截至2026年6月30日止6个月净利润介乎7亿至8亿元人民币(下同)，去年同期录得净亏损约6300万元。紫金矿业高开2.86%，公司发盈喜，预期2026年半年度实现归属于上市公司股东的净利润约391亿元人民币(下同)，与上年同期233亿元相比，增加约158亿元，增幅约68%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzMyOTI2MTc2NzYxOTM1NTM3.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985553","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU1831875114.USD","01044","LU0856984785.SGD","SG9999004220.SGD","SG9999000459.SGD","LU2097828631.EUR","83115","LU0163747925.USD","LU1571399168.USD","LU2778985437.USD","LU1235295612.USD","LU0431992006.USD","LU0228367735.SGD","BK1615","LU1515016050.SGD","LU2929501877.USD","SGXZ62798434.SGD","BK1575","SG9999001051.SGD","LU0329678170.USD","BK1249","LU0048580855.USD","LU0620787316.HKD","LU1242518931.SGD","BK1589","02565","LU0052756011.USD","LU0737861772.HKD","LU1769817179.HKD","LU0359201612.USD","LU0197773673.USD","BK1180","BK1607","LU0197773160.USD","LU1051768304.USD","LU0828237940.HKD","LU0890818403.SGD","LU2177674079.SGD","BK1588","LU1720050803.USD","HK0000306685.HKD","HK0000320223.HKD","LU0345775950.USD","ZIJMY","LU0329678337.USD","LU0345780521.USD","LU0417516902.SGD","LU1366334578.USD","LU0871576103.HKD","LU0307460666.USD","LU1048588211.SGD","LU0823426480.USD","LU0572944931.SGD","LU0128522157.USD","LU0140636845.USD","LU0630378692.HKD","LU1105468828.SGD","LU1481107354.HKD","LU2097828805.USD","SG9999004311.SGD","BK1544","00823","LU0211977185.USD","LU0593848301.USD","LU1064131342.USD","BK1098","LU0561508036.HKD","07300","03115","LU0096374516.USD","LU1961090484.USD","SG9999001903.USD","PMRTY","LU0164880469.USD","BK1193","LU1366334651.USD","BK1592","LU1988902786.USD","LU0328353924.USD","603993","LU0862451837.USD","LU0651946864.USD","LU1046422090.SGD","LU0348735423.USD","LU0039217434.USD","LU0128525689.USD","LU0345780281.USD","LU1211504680.USD","LU1048596156.SGD","LU0831093199.SGD","BK1578","LU1769817096.USD","BK1521","LU0106252389.USD","LU0348816934.USD","LU0348825331.USD","07200","HEGIY","601899","BK1172","LU1303224171.USD","LU0821914370.USD","LU0634319403.HKD","LU2097828557.USD","00666","BK1510","01928","02833","LU0640798160.USD","09888","LU0251144936.SGD","LU1224709979.USD","SG9999001226.SGD","WHGLY","LU0348767384.USD","SG9999002950.SGD","LU2148510915.USD","02685","LU0266512127.USD","LU0572940350.SGD","BIDU","LU1794554557.SGD","SG9999001069.SGD","LU0862451753.SGD","LU0149721374.USD","LU0469268626.HKD","LU0072462343.USD","LU1166156734.SGD","LU2226246903.HKD","LU0165289439.USD","LU0456854461.SGD","HK0000306701.USD","LU0359201885.HKD","SGXZ86797644.SGD","00992","07500","CKHUY","LU0359202008.SGD","BK1594","LU0828237510.HKD","LU0541501648.USD","LU0611395673.USD","LU0264606111.USD","LU0348814723.USD","LU1719994722.HKD","89888","LU3063872942.SGD","LU0345776255.USD","LU0797268264.HKD","HHImain","LU0918141887.USD","HK0000320264.USD","IE0034224299.USD","LU0327786744.USD","LU1808992512.USD","LU2097828474.EUR","LU2476274308.USD","BK1604","BK1116","BK1256","LU0886674414.USD","LU0762540952.USD","BK1526","LU0164939612.USD","LU1188198961.HKD","BK1609","LU1770034418.SGD","BK1505","MCHmain","IE00B0JY6N72.USD","IE0032431581.USD","LU1880383366.USD","LU2187417386.USD","IE00B3M56506.USD","BK1569","LU0181495838.USD","LU1770036033.HKD","BK1237","SCHYY","LU1282648689.USD","LU2351347302.SGD","00001","LU0541502299.USD","BK1543","09992","03121","LU0043850808.USD","LU0370786039.SGD","LU0531971595.HKD","02800","LU0672654166.SGD","BK1190","LU0320764755.SGD","LU0918141705.HKD","LU0456827905.SGD","LU0029875118.USD","LU0061477393.USD","LU0231483743.USD","513600","03419","BK1161","LU2039709279.SGD","LU0049112450.USD","LU2008162690.USD","LNVGY","BK1198","LU1328615791.USD","LU0572939691.SGD","LU0229945570.USD","02899","LU1064131003.USD","LU0082770016.SGD","LU0762542818.HKD","LU0228659784.USD","82800","LU0499858438.USD","03037","LU0417516738.SGD","LU0979878070.USD","LU0287142896.SGD","LU0266512473.USD","BK1500","LU0320764599.SGD","LU0708995583.HKD","LU0868486357.SGD","SG9999014674.SGD","LU1064130708.USD","LU0543330566.HKD","LU0348827113.USD","03993","LU0819121731.USD","BK1224","BK1601","LU1251922891.USD","LU0326950275.SGD","LU1115378108.SGD","LU0791590937.USD","SG9999002828.SGD","LU2242644610.SGD","LU2543165471.USD","LU0052750758.USD","SGXZ90724238.SGD","LU2264538146.SGD","LU0082770016.USD","LU0164865239.USD","01876","00288","BK1207","80992","BK1557","LU0048597586.USD","LU0348766576.USD","LU0499858602.USD","LU0791591158.USD","LU1023057109.AUD","LU0540923850.HKD","LU0244354667.USD","LU2213484517.USD","LU2399975544.HKD","LU1267930227.SGD","LU1880383440.USD","BK1096","HSI","LU0310800965.SGD","BK1095","BK1603","LU0463099449.HKD","LU0588546209.SGD","LU0823426308.USD","LU1504937902.USD","LU2097828714.EUR","09115","HSTECH","BK1587","LU0315179316.USD","LU0173614495.USD","TCHI","LU1242518857.USD","LU0106959298.USD","01070","LU0274383008.USD","SG9999002463.SGD","BK1230","LU0762541174.USD","LU0630378429.USD","LU0049853897.USD","LU0737861699.HKD","LU0702159699.USD","LU0543330483.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650730908","title":"派格生物（02565）牵手Rani：口服化打开下一代代谢资产的全球重估空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2650730908","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650730908?lang=zh_cn&edition=full","pubTime":"2026-07-10 08:45","pubTimestamp":1783644300,"startTime":"0","endTime":"0","summary":"在核心产品维培那肽进入商业化阶段后，派格生物正在为其下一代代谢创新管线叠加新的产品形态和海外开发路径。智通财经APP获悉，近日，港股上市公司派格生物与美国纳斯达克上市公司Rani Therapeutics签署谅解备忘录。派格生物已经形成由商业化产品维培那肽、超长效平台CR059以及以APGP6为代表的下一代肥胖候选资产组成的梯度化管线。过去，肥胖药物的竞争主要围绕体重下降幅度展开。CR059代表的是月级乃至季度","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02565"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650970703","title":"派格生物医药-B(02565.HK)携手纳斯达克上市公司RANI THERAPEUTICS推进多项代谢创新资产口服化","url":"https://stock-news.laohu8.com/highlight/detail?id=2650970703","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650970703?lang=zh_cn&edition=full","pubTime":"2026-07-10 08:13","pubTimestamp":1783642413,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07522","09834","03034","03455","09086","BK1147","BK1161","02565","02834","03086","07568","07261","07266"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650097022","title":"派格生物：与纳斯达克上市公司Rani Therapeutics签署谅解备忘录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650097022","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650097022?lang=zh_cn&edition=full","pubTime":"2026-07-10 08:06","pubTimestamp":1783641978,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4539","BK4007","BK1161","02565","RANI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139784250","title":"派格生物医药-B更新2026年6月股份变动月报表，注册股本增至391,091,532股","url":"https://stock-news.laohu8.com/highlight/detail?id=1139784250","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139784250?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:51","pubTimestamp":1783327878,"startTime":"0","endTime":"0","summary":"派格生物医药(杭州)股份有限公司于2026年7月6日披露2026年6月股份变动月报表，报告期为截至2026年6月30日。公告显示，本月公司H股及非上市股份均有相应变动。公司披露，101,702,051股非上市股份已于2026年6月25日完成转为H股，并自2026年6月26日起在香港联交所上市。上述变动后，公司本月底注册股本合计为391,091,532股。\\n\\n本次月报由联席公司秘书黄一峰签署，并披露于香港联交所。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02565"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pegbio.com","stockEarnings":[{"period":"1week","weight":-0.0391},{"period":"1month","weight":0.1811},{"period":"3month","weight":-0.7864},{"period":"6month","weight":-0.9056},{"period":"1year","weight":-0.5872},{"period":"ytd","weight":-0.9074}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"派格生物医药（杭州）股份有限公司是一家主要从事研究及开发慢性病创新疗法的中国公司。该公司的主要产品PB-119是自主开发、接近商业化阶段的长效胰高血糖素样肽1（GLP-1，一种降低血糖水平的肽类激素）受体激动剂。该公司的候选产品包括PB-718、PB-1902、PB-722、PB-2301和PB-2309。该公司的产品主要用于治疗2型糖尿病（T2DM）、肥胖症、非酒精性脂肪性肝炎（NASH）、阿片类药物引起的便秘（OIC，使用阿片类药物引起的胃肠道疾病）及先天性高胰岛素血症（一种罕见的内分泌疾病，患者持续出现低血糖症）等常见慢病及代谢疾病。","exchange":"SEHK","name":"派格生物医药-B","nameEN":"PEGBIO CO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"派格生物医药-B,02565,派格生物医药-B股票,派格生物医药-B股票老虎,派格生物医药-B股票老虎国际,派格生物医药-B行情,派格生物医药-B股票行情,派格生物医药-B股价,派格生物医药-B股市,派格生物医药-B股票价格,派格生物医药-B股票交易,派格生物医药-B股票购买,派格生物医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"派格生物医药-B(02565)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供派格生物医药-B(02565)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}